Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

ELEM Virtual Heart Populations for Supercomputers

Project description

Clinical trials with Virtual Human Twins

The development of novel therapies, drugs, and medical devices often involves complex and time-consuming clinical trials that carry risks. The process also relies heavily on animal testing and early human trials, which can slow progress and raise ethical concerns. Evaluating the safety and efficacy of these treatments requires accurate, timely data from diverse populations. In this context, the EIC-funded ELVIS project addresses these challenges with V.Heart a supercomputer-based platform that performs massive in silico clinical trials using digital avatars based on real medical data. This cutting-edge technology assesses various therapies by simulating thousands of scenarios, accelerating clinical research, and reducing risks. V.Heart aims to create digital twins for precision medicine, offering faster, safer, and more personalised healthcare solutions.

Objective

ELEMs V.Heart is a supercomputer-based platform to perform massive in-silico clinical trials on populations of digital avatars generated through a database of real medical data, to study the outcomes of different therapies. It assesses the safety and efficacy of novel therapeutics, devices or drugs, by computing thousands of scenarios. Current capability covers classic or leadless pacing and cardiac pumps and cardiac safety of drugs. Our plan is to add new therapies whilst increasing the range of our patented virtual population technology. V.Heart generates unparalleled medical insights and new evidence for biomedical professionals whilst shortening time to market and reducing business and patient risks. It narrows the scope for animal testing and tapers real human trials by evaluating clinical study endpoints much faster and earlier in the development process. Eventually, digital avatars become a Digital Twin of any given patient used as a predictive tool for precision medicine.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2022-ACCELERATOR-01

See all projects funded under this call

Coordinator

ELEM BIOTECH SL
Net EU contribution
€ 2 482 096,75
Address
CALLE ROSSELLO 36 4O 1A
08029 Barcelona
Spain
SME
Yes
Region
Este Cataluña Barcelona
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 3 545 852,50